Johnson & Johnson (NYSE:JNJ) Shares Sold by Tilia Fiduciary Partners Inc.

Tilia Fiduciary Partners Inc. lessened its position in shares of Johnson & Johnson (NYSE:JNJ) by 3.3% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,052 shares of the company’s stock after selling 103 shares during the quarter. Tilia Fiduciary Partners Inc.’s holdings in Johnson & Johnson were worth $506,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in JNJ. Lantz Financial LLC boosted its holdings in Johnson & Johnson by 3.3% in the 1st quarter. Lantz Financial LLC now owns 11,974 shares of the company’s stock worth $1,986,000 after buying an additional 377 shares during the last quarter. Sulzberger Capital Advisors Inc. acquired a new stake in Johnson & Johnson in the 4th quarter worth about $453,000. Horan Securities Inc. boosted its holdings in Johnson & Johnson by 1.3% in the 4th quarter. Horan Securities Inc. now owns 7,178 shares of the company’s stock worth $1,038,000 after buying an additional 90 shares during the last quarter. Strategic Financial Concepts LLC boosted its holdings in Johnson & Johnson by 57.9% in the 4th quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company’s stock worth $501,000 after buying an additional 1,271 shares during the last quarter. Finally, State of Wyoming boosted its holdings in Johnson & Johnson by 205,580.0% in the 4th quarter. State of Wyoming now owns 10,284 shares of the company’s stock worth $1,487,000 after buying an additional 10,279 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Royal Bank of Canada reiterated an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a report on Thursday. Leerink Partners cut Johnson & Johnson from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $169.00 to $153.00 in a report on Tuesday, May 13th. Sanford C. Bernstein restated a “market perform” rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Morgan Stanley boosted their target price on Johnson & Johnson from $164.00 to $169.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 16th. Finally, Raymond James lowered their target price on Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating on the stock in a report on Monday, April 14th. Eleven investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $170.88.

Johnson & Johnson Stock Up 0.9%

JNJ stock opened at $155.02 on Monday. The firm has a market cap of $372.99 billion, a PE ratio of 23.31, a PEG ratio of 2.56 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The firm’s 50 day moving average price is $153.59 and its 200-day moving average price is $153.67. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.59 by $0.18. The firm had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. On average, equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be given a $1.30 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a yield of 3.35%. Johnson & Johnson’s payout ratio is presently 57.84%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.